Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 14;22(18):9905.
doi: 10.3390/ijms22189905.

Cognitive Deficit in Schizophrenia: From Etiology to Novel Treatments

Antón L Martínez  1 , José Brea  1 , Sara Rico  1 , María Teresa de Los Frailes  2 , María Isabel Loza  1
Affiliations
Review

Cognitive Deficit in Schizophrenia: From Etiology to Novel Treatments

Antón L Martínez et al. Int J Mol Sci. .

Abstract

Schizophrenia is a major mental illness characterized by positive and negative symptoms, and by cognitive deficit. Although cognitive impairment is disabling for patients, it has been largely neglected in the treatment of schizophrenia. There are several reasons for this lack of treatments for cognitive deficit, but the complexity of its etiology-in which neuroanatomic, biochemical and genetic factors concur-has contributed to the lack of effective treatments. In the last few years, there have been several attempts to develop novel drugs for the treatment of cognitive impairment in schizophrenia. Despite these efforts, little progress has been made. The latest findings point to the importance of developing personalized treatments for schizophrenia which enhance neuroplasticity, and of combining pharmacological treatments with non-pharmacological measures.

Keywords: antipsychotics; cognitive deficit; mechanisms of action; pharmacology; schizophrenia.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Mueser K.T., McGurk S.R. Schizophrenia. Lancet. 2004;363:2063–2072. doi: 10.1016/S0140-6736(04)16458-1. - DOI - PubMed
    1. Carrà G., Crocamo C., Angermeyer M., Brugha T., Toumi M., Bebbington P. Positive and negative symptoms in schizophrenia: A longitudinal analysis using latent variable structural equation modelling. Schizophr. Res. 2019;204:58–64. doi: 10.1016/j.schres.2018.08.018. - DOI - PubMed
    1. Chang C.-Y., Luo D.-Z., Pei J.-C., Kuo M.-C., Hsieh Y.-C., Lai W.-S. Not Just a Bystander: The Emerging Role of Astrocytes and Research Tools in Studying Cognitive Dysfunctions in Schizophrenia. Int. J. Mol. Sci. 2021;22:5343. doi: 10.3390/ijms22105343. - DOI - PMC - PubMed
    1. Dollfus S., Lyne J. Negative symptoms: History of the concept and their position in diagnosis of schizophrenia. Schizophr. Res. 2017;186:3–7. doi: 10.1016/j.schres.2016.06.024. - DOI - PubMed
    1. Bora E. Peripheral inflammatory and neurotrophic biomarkers of cognitive impairment in schizophrenia: A meta-Analysis. Psychol. Med. 2019;49:1971–1979. doi: 10.1017/S0033291719001685. - DOI - PubMed

MeSH terms